Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).
Phase:
PHASE1
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
M.D. Anderson Cancer Center National Cancer Institute (NCI)